HEPATOLOGY肝脏病学
HEPATOLOGY(英文缩写 HEPATOLOGY),ISSN 0270-9139,eISSN 1527-3350,中文译名:肝脏病学 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-11-01 至 2026-10-31，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 17.298 | Q1 |
| 2022 | 13.500 | Q1 |
| 2023 | 12.900 | Q1 |
| 2024 | 15.800 | Q1 |
| 2025 | 18.000 | Q1 |
HEPATOLOGY 最新收录文献
-
1. Efficacy and safety of an 8-week bemnifosbuvir and ruzasvir regimen in chronic hepatitis C: Results from a Phase 2 study.
1. 8周贝姆尼福布韦联合鲁扎斯韦方案治疗慢性丙型肝炎的疗效和安全性：一项2期研究结果PMID:日期:2026-10-02Bemnifosbuvir and ruzasvir are potent pan-genotypic inhibitors of the hepatitis C virus (HCV) NS5B polymerase and NS5A protein, respectively. This single-arm, Phase 2 study evaluated the efficacy and safety of bemnifosbuvir and ruzasvir in treatment-naïve patients with chronic HCV infection of any genotype, with or without compensated cirrhosis. Patients received bemnifosbuvir 550 mg and ruzasvir 180 mg once daily for 8 weeks (intention-to-treat [ITT] population). The primary efficacy endpoint was the proportion of patients achieving sustained virologic response at 12 weeks post treatment (SVR12) in the Pharmacokinetic and Pill Compliant Per-Protocol (PK/PC-PP) population. Secondary efficacy endpoints included SVR12 in the Efficacy Evaluable Per-Protocol (EE-PP; those with outcomes regardless of study drug adherence) and safety (all dosed) populations, virologic failure, and SVR24. Of the 275 patients enrolled and who received treatment with bemnifosbuvir and ruzasvir, 13% had compensated cirrhosis and 27% had NS5A resistance-associated substitutions (RASs) at baseline. SVR12 was 90% (248/275; 95% CI: 86-93%) in the ITT population, 98% (210/215; 95% CI: 95-99%) in the PK/PC-PP population, and 95% (245/259; 95% CI: 91-97%) in the EE-PP population. Five patients in the PK/PC-PP population experienced virologic failure (post-treatment relapse). No drug-related serious adverse events or premature treatment discontinuations due to drug-related adverse events were reported. An 8-week treatment with bemnifosbuvir and ruzasvir resulted in high rates of SVR12 across genotypes, regardless of the presence or absence of baseline RASs, and was well tolerated among treatment-naïve HCV patients.
-
2. TESERA: morphologic subtyping and prognostic stratification of hepatocellular carcinoma from H&E whole-slide images.
2. TESERA：基于H&E全切片图像的肝细胞癌形态学分型与预后分层PMID:日期:2026-10-02Hepatocellular carcinoma (HCC) remains among the most lethal cancers worldwide, yet few tools exist to characterize HCC biology and stratify patient risk at the point of care. We developed TESERA (Tissue Encoded Subtype Elucidation and Risk Assessment), a computational pathology framework that derives both unsupervised subtypes and a prognostic index directly from hematoxylin and eosin (H&E) whole-slide images (WSIs). Applied to The Cancer Genome Atlas Liver Hepatocellular Carcinoma (TCGA-LIHC) cohort, unsupervised clustering of TESERA embeddings grouped tumors into Tissue Encoded Subtypes (TES1 and TES2) associated with different overall survival (OS; TES2 HR=4.20). TES1, the favorable-prognosis subtype, was enriched for metabolic pathways and CTNNB1 mutations, while TES2 was enriched for proliferative pathways and TP53 mutations. To predict patient-level survival outcomes, we trained a supervised model, the TESERA morphologic index (TESERA-MI), on TESERA embeddings, which predicted both OS (HR=3.17) and disease-free survival (HR=2.19) in TCGA-LIHC. TESERA-MI achieved the highest discrimination in a head-to-head comparison with clinical variables and molecular markers (C-index, 0.73; 1-, 3-, and 5-year AUROCs, 0.82, 0.80, and 0.79), remained independently prognostic after multivariable adjustment (HR=2.97), and stratified OS in an independent in-house cohort (HR=2.16). Released as a publicly accessible pipeline applicable to H&E WSIs, TESERA unifies morphologically derived metabolism-versus-proliferation subtypes with an externally validated, prognostic morphologic index competitive with existing clinical and molecular markers. These findings position routine histology as a low-cost, widely available substrate for biology-aware risk stratification in HCC.
-
3. Hepatogenesis through interspecies chimerism - An immunological path distinct from xenotransplantation.
3. 通过种间嵌合体的肝发生——一条不同于异种移植的免疫学路径PMID:日期:2026-10-02该文献暂无摘要。
-
10. Reciprocal cross-species infection potential of human and domestic cat hepatitis B viruses.
10. 人和家猫乙型肝炎病毒的交互跨物种感染潜力PMID:日期:2026-10-01The host tropism of human hepatitis B virus (HBV) limits cross-species transmission and hampers animal model development. Recently identified domestic cat hepatitis B virus (DCHBV) shares high similarity with HBV in viral receptor-binding motifs and their cognate receptor, sodium taurocholate co-transporting polypeptide (NTCP), suggesting potential for cross-species transmission. This study aimed to assess the reciprocal transmission capacity between HBV and DCHBV and identify key determinants of host specificity. Transfection of Huh7 cells with a DCHBV infectious clone alone, or co-transfection with hepatitis delta virus (HDV) cDNA, produced DCHBV or HDV pseudotyped with DCHBV envelope proteins (DCHDV), respectively. Cross-species infection was assessed using HepG2 cells expressing human or cat NTCP (HepG2-hNTCP/cNTCP), as well as primary human or cat hepatocytes (PHH/PCH). HBV and HDV efficiently infected HepG2-cNTCP cells and PCH. In contrast, DCHBV/DCHDV failed to infect HepG2-hNTCP cells and PHH, despite successful infection of PCH. All the infections could be inhibited by the myristoylated preS1/2-48 peptide, indicating that cNTCP is the bona fide receptor for DCHBV infection. Inefficient internalization may restrict DCHBV/DCHDV infection of human hepatocytes. Using chimeric envelope proteins, we found that the region spanning residues 16-49 of DCHBV preS1 restricts its transmission to human hepatocytes. Additionally, overexpression of cat orthologs of the proposed HBV cofactors EGFR and NRP1 did not rescue the infection. These findings suggest a marginal zoonotic risk of DCHBV for humans and support domestic cats as a potential immunocompetent animal model for HBV research.